May 6, 2008--A new treatment option – Ferriprox Oral Solution - is now available to patients suffering from thalassaemia major, a rare genetic disease with only 50 percent of the patients surviving the age of 35 years1. Thalassaemia patients require blood transfusions to survive, which leads to damaging iron accumulation in the tissues, especially the heart. Ferriprox (deferiprone) is an iron chelator that effectively removes the excess iron from the body caused by blood transfusions. A liquid formulation of Ferriprox is now available in the UK, Germany, Denmark, Norway and Sweden.
The details can be read here.
No comments:
Post a Comment